Cure My Disease

Don't miss your cure!

 Log in / Sign up

10-Year study to track rare brain disease in 500 koreans

NCT ID NCT07497867

Knowledge-focused Sponsor: Jeju National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This 10-year study will follow 500 Korean adults with CADASIL, a genetic brain disease that causes strokes and dementia. Researchers will track symptoms, brain scans, memory tests, and genetic information to understand how the disease progresses in Koreans. The goal is to improve care for patients and families worldwide. No new treatment is being tested.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal how CADASIL progresses in Korean patients and point toward better ways to manage the disease.
What could go wrong
This is an observational study, not a treatment trial. It will not test any new drug or therapy, so direct patient benefits are unlikely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Dec 2040

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Korean adults (≥19 years) with genetically confirmed or clinically suspected CADASIL (NOTCH3 mutation). Multicenter prospective cohort recruited from 28 hospitals across Korea. Approximately 500 participants will be followed for 10 years.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 19 years * CADASIL suspected or confirmed by genetic testing (NOTCH3 mutation) * Able to provide written informed consent (participant or legally authorized representative) Exclusion Criteria: * Contraindication to MRI (claustrophobia, metal implants, pacemaker) * Acute ischemic or hemorrhagic stroke within 180 days prior to enrollment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cadasil are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cerebral arteriopathy with subcortical infarcts and leukoencephalopathy cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 Cerebral Small Vessel Diseases Leukoencephalopathies stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cadasil Cerebral autosomal dominant arteriopatie with subcortical infarcts and leukoencephalopathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Jeju National University Hospital

    RECRUITING

    Jeju City, Jeju-do, 63241, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.